INMD

Based on InMode Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does InMode do?

InMode designs and sells energy-based medical devices used by physicians for aesthetic and minimally invasive procedures. Its platforms use proprietary radiofrequency technology to perform body contouring, skin tightening, facial rejuvenation, and women's health treatments. The company sells both capital equipment and recurring consumables to clinics worldwide.

Does INMD pay dividends?

InMode does not currently pay a dividend. The company retains its earnings, which is common among medical device companies that prioritize reinvestment in product development and geographic expansion over returning cash to shareholders through distributions.

When does INMD report earnings?

InMode reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact dates and upcoming earnings schedules, check InMode's investor relations page directly, as our data source does not carry forward-looking calendar events.

Is INMD a good stock to buy?

UQS Score rates INMD as Good overall. The Valuation pillar is Attractive and the Risk pillar is Strong, which are positive signals. However, the Moat and Growth pillars are both Weak, indicating meaningful headwinds. Whether those trade-offs suit your portfolio depends on your own investment criteria — view the full pillar breakdown on UQS Pro.

Is INMD overvalued?

Based on the UQS Valuation pillar, INMD is rated Attractive, suggesting the stock is not trading at an obvious premium relative to its fundamentals. This stands out in the medical device sector, where growth-oriented peers often carry elevated valuations. The complete valuation metrics are available to UQS Pro members.

How does INMD compare to its competitors?

InMode occupies a focused niche in aesthetic and minimally invasive radiofrequency devices, which differentiates it from broader medical device companies like Integra LifeSciences. Compared to surgical robotics or neurodiagnostic peers, InMode's revenue is more concentrated in elective, consumer-driven procedures. See the side-by-side UQS pillar comparison on this page for more context.

What is INMD's market cap bracket?

InMode is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large-cap or mega-cap medical device peers.

Who founded InMode?

InMode was incorporated in 2008 under the name Invasix Ltd. and rebranded to InMode Ltd. in November 2017. Founding details and executive history are publicly available through the company's official filings and investor relations materials.

Is INMD a long-term quality investment?

As a long-term quality indicator, INMD's UQS profile presents a mixed picture. The Strong Risk pillar and Attractive Valuation are encouraging for durability, but the Weak Moat and Weak Growth pillars raise questions about the company's ability to sustain competitive advantages and expand revenues over time. UQS Pro members can access the full multi-pillar analysis.

What is the main competitive advantage of InMode?

InMode's core differentiation lies in its proprietary radiofrequency-based technology platform, which enables minimally invasive procedures with less downtime than traditional surgical alternatives. However, the UQS Moat pillar rates this advantage as Weak, reflecting competitive pressure from other energy-based device makers in the aesthetic medicine space.

What sector does INMD belong to?

InMode operates in the Healthcare sector, specifically within medical devices and aesthetic technology. Its products sit at the intersection of elective medicine and technology-driven clinical procedures, making it sensitive to both healthcare trends and consumer discretionary spending patterns.

Is INMD a growth stock or value stock?

Based on the UQS pillar profile, INMD leans toward value characteristics at this stage. The Valuation pillar is Attractive while the Growth pillar is Weak, suggesting the market has already discounted slower expansion. Investors seeking high-growth medical device exposure may find the profile less compelling than those looking for reasonably priced quality.

InMode Ltd. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.

InMode Ltd. faces growth headwinds with declining or stagnant revenue trends.

InMode Ltd. carries minimal financial risk with conservative leverage and strong solvency.

InMode Ltd. appears attractively valued relative to its earnings, cash flows, and sector peers.

InMode Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for INMD.

The UQS (Unified Quality Score) for InMode Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses InMode Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether InMode Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.